Dr. Endsley is a Director of Early Development supporting discovery through FIH dose prediction and justification activities, IND, and early clinical trials focused on large molecule complex biologic therapeutics across many therapeutic areas at Certara since 2018.

Prior to Certara, he was the BAPK project representative at Bayer’s former San Francisco Research site supporting novel complex biologics
projects. Prior to Bayer, he worked at SRI International supporting PK study design and analysis for large and small molecule projects, both internal and via the numerous NIH preclinical development contracts held by SRI. Aaron has a BS degree in Microbiology and PhD in Pharmaceutical Sciences both from the University of Washington.